Share the Tech If mRNA vaccine technology from Moderna, BioNTech and Pfizer were shared, manufacturers in low- and middle-income countries could produce vaccines for global pandemic preparedness, as well as diseases of concern such as HIV, TB and malaria.
Shailly Gupta “Should repurposed drugs demonstrate efficacy against COVID-19, they could be manufactured profitably at very low costs,” the authors wrote, giving range of between $1 and $29 per course of treatment. in.reuters.com/article/health… 02:54 - 10 Apr 2020